| Schedule of reportable segment net income (loss) |
The Company's reportable segment net income (loss) for the three and six months ended June 30, 2025 and 2024, consisted of the following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
June 30, |
|
|
Six Months Ended June 30, |
|
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
Significant segment expenses: |
|
|
|
|
|
|
|
|
|
|
|
Live biotherapeutics platform |
$ |
5,808 |
|
|
$ |
6,687 |
|
|
$ |
10,931 |
|
|
$ |
15,851 |
|
SER-155 |
|
1,044 |
|
|
|
2,207 |
|
|
|
1,621 |
|
|
|
4,607 |
|
R&D personnel-related (including stock-based compensation) |
|
6,084 |
|
|
|
6,906 |
|
|
|
12,202 |
|
|
|
14,751 |
|
G&A personnel-related (including stock-based compensation) |
|
3,725 |
|
|
|
5,698 |
|
|
|
7,898 |
|
|
|
12,339 |
|
Professional fees |
|
2,155 |
|
|
|
2,091 |
|
|
|
5,335 |
|
|
|
4,719 |
|
Facility-related and other |
|
4,373 |
|
|
|
5,276 |
|
|
|
8,908 |
|
|
|
10,951 |
|
Gain on sale of VOWST Business |
|
(185 |
) |
|
|
— |
|
|
|
(52,366 |
) |
|
|
— |
|
Other segment expense (income) (1) |
|
(3,149 |
) |
|
|
(2,669 |
) |
|
|
(7,356 |
) |
|
|
(4,119 |
) |
Net income (loss) from continuing operations |
|
(19,855 |
) |
|
|
(26,196 |
) |
|
|
12,827 |
|
|
|
(59,099 |
) |
Net (loss) from discontinued operations, net of tax (2) |
|
— |
|
|
|
(6,674 |
) |
|
|
— |
|
|
|
(13,904 |
) |
Net income (loss) |
$ |
(19,855 |
) |
|
$ |
(32,870 |
) |
|
$ |
12,827 |
|
|
$ |
(73,003 |
) |
[1] Other segment (expense) income includes manufacturing services expenses, research and development expenses on early stage programs, interest income and other (expense) income, net. [2] See Note 3, Discontinued Operations and TSA, for further details.
|